WO1997026880A3 - Utilisation d'une combinaison de delavirdine et d'un ou plusieurs inhibiteurs de protease chez des patients contamines par le vih-1 - Google Patents

Utilisation d'une combinaison de delavirdine et d'un ou plusieurs inhibiteurs de protease chez des patients contamines par le vih-1 Download PDF

Info

Publication number
WO1997026880A3
WO1997026880A3 PCT/US1996/019222 US9619222W WO9726880A3 WO 1997026880 A3 WO1997026880 A3 WO 1997026880A3 US 9619222 W US9619222 W US 9619222W WO 9726880 A3 WO9726880 A3 WO 9726880A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
delavirdine
protease inhibitors
combination
infected patients
Prior art date
Application number
PCT/US1996/019222
Other languages
English (en)
Other versions
WO1997026880A2 (fr
Inventor
William W Freimuth
Original Assignee
Upjohn Co
William W Freimuth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co, William W Freimuth filed Critical Upjohn Co
Priority to AU18203/97A priority Critical patent/AU723563B2/en
Priority to JP09526831A priority patent/JP2000503986A/ja
Priority to EP96945781A priority patent/EP0877613A2/fr
Publication of WO1997026880A2 publication Critical patent/WO1997026880A2/fr
Publication of WO1997026880A3 publication Critical patent/WO1997026880A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé de traitement d'un sujet humain contaminé par le virus VIH-1 nécessitant un tel traitement, consistant à administrer audit sujet une dose de délavirdine (I) efficace contre le VIH-1 ou bien un sel pharmaceutiquement acceptable de celle-ci, et une dose d'un ou de plusieurs inhibiteurs de protéase efficaces contre le VIH-1.
PCT/US1996/019222 1996-01-26 1996-12-10 Utilisation d'une combinaison de delavirdine et d'un ou plusieurs inhibiteurs de protease chez des patients contamines par le vih-1 WO1997026880A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU18203/97A AU723563B2 (en) 1996-01-26 1996-12-10 Use of a combination of delavirdine and one or more protease inhibitors in HIV-1 infected patients
JP09526831A JP2000503986A (ja) 1996-01-26 1996-12-10 Ｈｉｖ―１陽性であるヒトにおけるデラビルジンおよびプロテアーゼ・インヒビターの使用
EP96945781A EP0877613A2 (fr) 1996-01-26 1996-12-10 Utilisation d'une combinaison de delavirdine et d'un ou plusieurs inhibiteurs de protease chez des patients contamines par le vih-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1067696P 1996-01-26 1996-01-26
US60/010,676 1996-01-26

Publications (2)

Publication Number Publication Date
WO1997026880A2 WO1997026880A2 (fr) 1997-07-31
WO1997026880A3 true WO1997026880A3 (fr) 1997-09-12

Family

ID=21746876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/019222 WO1997026880A2 (fr) 1996-01-26 1996-12-10 Utilisation d'une combinaison de delavirdine et d'un ou plusieurs inhibiteurs de protease chez des patients contamines par le vih-1

Country Status (5)

Country Link
EP (1) EP0877613A2 (fr)
JP (1) JP2000503986A (fr)
AU (1) AU723563B2 (fr)
CA (1) CA2242761A1 (fr)
WO (1) WO1997026880A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2140329B1 (es) * 1997-12-04 2000-10-16 Univ Granada Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.
KR100579792B1 (ko) 1998-05-13 2006-05-12 동화약품공업주식회사 신규 2,5-피리딘디카복실산 유도체
ATE401313T1 (de) * 2000-08-14 2008-08-15 Teva Pharma Herstellung von risperidon
GB0504314D0 (en) * 2005-03-02 2005-04-06 Glaxo Group Ltd Novel polymorph
CN100463907C (zh) * 2006-02-10 2009-02-25 上海医药工业研究院 一种1-(5-硝基-1h-吲哚-2-羰基)-4-{3-[(1-甲基乙基)氨基]-2-吡啶}哌嗪的制备方法
DE102011113749A1 (de) * 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0691345A2 (fr) * 1994-07-05 1996-01-10 Bristol-Myers Squibb Company Combinaisons d'inhibiteurs de la protéase d'HIV

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0691345A2 (fr) * 1994-07-05 1996-01-10 Bristol-Myers Squibb Company Combinaisons d'inhibiteurs de la protéase d'HIV

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. GILDEN: "Delavirdine/Proteases Inhibitor Interactions", GHMC TREATMENT ISSUES, vol. 10, no. 9, September 1996 (1996-09-01), pages 10 - 12, XP002033844 *
LARDER B A: "VIRAL RESISTANCE AND THE SELECTION OF ANTIRETROVIRAL COMBINATIONS", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, vol. 10, no. SUPPL. 01, 1995, pages S28 - S33, XP000653837 *
PAGANO P J ET AL: "IN VITRO INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 BY A COMBINATION OF DELAVIRDINE (U-90152) WITH PROTEASE INHIBITOR U-75875 OR INTERFERON-ALPHA", JOURNAL OF INFECTIOUS DISEASES, vol. 171, no. 1, 1 January 1995 (1995-01-01), pages 61 - 67, XP000565844 *

Also Published As

Publication number Publication date
JP2000503986A (ja) 2000-04-04
CA2242761A1 (fr) 1997-07-31
AU1820397A (en) 1997-08-20
WO1997026880A2 (fr) 1997-07-31
AU723563B2 (en) 2000-08-31
EP0877613A2 (fr) 1998-11-18

Similar Documents

Publication Publication Date Title
TW371628B (en) Composition for treating condyloma acuminata
EP1273298A3 (fr) Ritonavir en combinaison avec un inhibiteur de la protéase du VIH additionnel pour le traitement du SIDA
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
MY121276A (en) Use of glp-1 or analogs to abolish catabolic changes after surgery
TW200602350A (en) Methods and compositions for treating hepatitis C virus
PT880350E (pt) Tratamento de esclerose multipla
ID27502A (id) Turunan-turunan 3-(amino-atau aminoalkil) piridinon dan penggunannya untuk pengobatan penyakit-penyakit yang berkaitan dengan hiv
UA41355C2 (uk) Засіб для лікування нейро-сніду
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
AU1794601A (en) Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
HUP0203682A2 (hu) Eljárás foszfodiészteráz-4 inhibitor beadására
ZA991029B (en) Composition and methods for treatment of hiv infections.
AP9801286A0 (en) Therapeutic compounds.
WO1997026880A3 (fr) Utilisation d'une combinaison de delavirdine et d'un ou plusieurs inhibiteurs de protease chez des patients contamines par le vih-1
BR9706938A (pt) Composto uso do mesmo formulação farmacêutica e processos para produzir o composto e para o tratamento ou a prevenção de sintomas ou efeitos de uma infecção virótica em um mamífero infectado incluindo um humano
CA2289017A1 (fr) Utilisation d'oxydes d'azote ou de promedicament a base de ces oxydes pour la prevention et le traitement therapeutique du cancer
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
NO981898L (no) Anvendelse av flupirtin for forhindring og behandling av sykdommer som er forbundet med skade pÕ det hematopotiske cellesystem
EA199700150A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC
WO2001010454A3 (fr) Composition et procedes de traitement d'infection par le vih
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
IL102815A0 (en) Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus
WO1999065511A3 (fr) COMPOSITION ET PROCEDE DE TRAITEMENT D'UNE INFECTION PAR $i(PSEUDOMONAS)
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2242761

Country of ref document: CA

Ref country code: CA

Ref document number: 2242761

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996945781

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 331086

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1996945781

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996945781

Country of ref document: EP